The general success of these studies is likely due to repetitive tumor cell killing by CAR T cells; additionally, the targeted CD19 is also expressed by healthy B cells which re-stimulate the CAR T cells independently of the targeted tumor cells. Here, CD19 is linked to neoplasm.